XML 43 R30.htm IDEA: XBRL DOCUMENT v3.10.0.1
Collaboration Agreements - Summary of Revenue Recognized Under the Collaboration Agreements - Additional Information 4 (Detail) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2018
Japan [Member]    
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]    
Remainder of transaction price, variable consideration from estimated future co-development billing   $ 2.6
Europe [Member]    
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]    
Remainder of transaction price, variable consideration from estimated future co-development billing   23.9
U.S./RoW and China [Member]    
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]    
Remainder of transaction price, variable consideration from estimated future co-development billing   251.3
Astellas Agreement [Member] | Japan [Member]    
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]    
Changes in revenue due to prior period adjustment $ 14.9 14.9
Astellas Agreement [Member] | Europe [Member]    
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]    
Changes in revenue due to prior period adjustment   (0.2)
AstraZeneca Agreements [Member] | U.S./RoW and China [Member]    
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]    
Changes in revenue due to prior period adjustment   $ (0.3)